Age: 72.0
Sex: F
Vaccine: COVID19, FLUX
Symptoms: Herpes zoster, Injection site erythema, Pain in extremity
Clinical narrative: Generalized itching developed on head and both arms. After three weeks eyes started itching and on Dec 4 a small sore developed above eye and on Dec 8th was diagnosed with Shingles.; A red reaction about three inches in diameter at injection site developed two days after the injection.; Arm was extremely sore; This spontaneous case was reported by a patient and describes the occurrence of HERPES ZOSTER (Generalized itching developed on head and both arms. After three weeks eyes started itching and on Dec 4 a small sore developed above eye and on Dec 8th was diagnosed with Shingles.), PAIN IN EXTREMITY (Arm was extremely sore) and INJECTION SITE ERYTHEMA (A red reaction about three inches in diameter at injection site developed two days after the injection.) in a 72-year-old female patient who received mRNA-1273.815 (SPIKEVAX 2023-2024) (batch no. AV3915B) for Pain and COVID-19 prophylaxis.    Co-suspect product included non-company product INFLUENZA VACCINE (FLU [INFLUENZA VACCINE]) for an unknown indication.    The patient's past medical history included COVID-19 (Have tested positive twice for COVID in April-May 2022.) in 2022, COVID-19 (Have tested positive for COVID in Jan 2023.) in January 2023 and Hormone level abnormal (Hormonal therapy (low Hormones)). Concurrent medical conditions included Osteoarthritis, Pre-diabetic and Hypothyroidism. Concomitant products included METFORMIN, ESTRADIOL, LEVOTHYROXINE, COLECALCIFEROL (VITAMINE D) and ASPIRIN [ACETYLSALICYLIC ACID] for an unknown indication.   On 10-Nov-2023, the patient received fourth dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form and dose of INFLUENZA VACCINE (FLU [INFLUENZA VACCINE]) (unknown route) 1 dosage form. On 12-Nov-2023,  after starting mRNA-1273.815 (SPIKEVAX 2023-2024), the patient experienced INJECTION SITE ERYTHEMA (A red reaction about three inches in diameter at injection site developed two days after the injection.). In November 2023, the patient experienced PAIN IN EXTREMITY (Arm was extremely sore). On 08-Dec-2023, the patient experienced HERPES ZOSTER (Generalized itching developed on head and both arms. After three weeks eyes started itching and on Dec 4 a small sore developed above eye and on Dec 8th was diagnosed with Shingles.). The patient was treated with IBUPROFEN (ADVIL [IBUPROFEN]) at an unspecified dose and frequency; DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL CHILDRENS) at a dose of 10 milligram; METHYLPREDNISOLONE at a dose of 4 milligram and VALACICLOVIR HYDROCHLORIDE (VALACYCLOVIR HYDROCHLORIDE) at a dose of 1 gram. In November 2023, PAIN IN EXTREMITY (Arm was extremely sore) had resolved. At the time of the report, HERPES ZOSTER (Generalized itching developed on head and both arms. After three weeks eyes started itching and on Dec 4 a small sore developed above eye and on Dec 8th was diagnosed with Shingles.) was resolving and INJECTION SITE ERYTHEMA (A red reaction about three inches in diameter at injection site developed two days after the injection.) outcome was unknown.        For mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown), the reporter did not provide any causality assessments.   Patient had red reaction about three inches in diameter at injection site. Generalized itching developed on head and both arms, after three weeks eyes started itching and on Dec 4 a small sore developed above eye and on Dec 8th she was diagnosed by PCP with Shingles.